Hospital Stocks Fall Up To 10% As Regulatory Concerns Weigh On Sector

Hospital stocks remained under pressure for a second straight session after the Supreme Court questioned steep markups on cancer drugs and asked the government to examine allegations that hospitals require patients to buy medicines from their own or designated pharmacies.

The scrutiny has added to concerns around hospital revenue from pharmacies, medicines and medical consumables. The government has also begun discussions with hospitals and the medical sector on rationalising trade margins for devices and consumables.

The regulatory focus comes after reports of hospital consumables being sold at markups several times above procurement prices. Items under scrutiny include syringes, IV sets, cardiac catheters, intraocular lenses, pacemakers and heart valves.

Hospital Stocks: Share Price Movement

Healthcare stocks have extended their recent losses, and major stocks have given negative returns this week as of 11:46 am on 01 October 2026 on the National Stock Exchange (NSE):

Why Are Cancer Drugs Under Scrutiny?

The Supreme Court recently flagged a 10-fold difference between the price to retailer and the maximum retail price of a cancer drug. At a subsequent hearing, the Bench questioned whether a uniform 16% margin cap could be applied across pharmaceutical products.

Oncology drugs account for around 4-6% of hospital revenue, making drug pricing an important area for hospital operators. The court's observations have raised questions over whether tighter controls could affect hospital pharmacy economics.

Medical Consumables Add To Regulatory Pressure

The government is separately examining the gap between procurement prices and declared MRPs for hospital consumables. The FDA Commissioner has called for guidelines defining a permissible gap.

The products being examined include:

• Disposable syringes and IV sets

• Cardiac catheters

• Intraocular lenses

• Pacemakers

• Heart valves

The potential impact will depend on how any pricing rules are structured and implemented. Hospitals also face different payment arrangements, with insured and publicly funded patients often covered through pre-negotiated package rates rather than headline MRPs. This means the effect of any eventual margin controls could vary across patient segments and hospital businesses.

Also Read - Market Midday, 01 October 2026: Benchmarks Trade In The Red